Jonix: demonstrated bactericidal efficacy of NTP technology against MDR microorganisms

MILAN ( - JONIX announces an important step forward in the fight against antimicrobial resistance (AMR): the Department of Molecular Medicine of the University of Padua, directed by Prof. Andrea Crisanti, has subjected the NTP technology in the Jonix CUBE device to laboratory testing, demonstrating its bactericidal efficacy against several MultiDrug Resistant (MDR) microorganisms.
Antonio Cecchi, CEO of JONIX, comments: "The experimentation conducted at the University of Padua expands the scope of Jonix NTP Technology, confirming it as a technology capable of opening important perspectives in "strategies aimed at reducing the risk of transmission of infections in healthcare and other collective contexts". The health sector, veterinary and other collective systems will find in JONIX devices a valuable ally in the important fight against Antibiotic Resistance. In Italy alone, there are 1,000 hospitals, 9,000 outpatient clinics, 10,000 residential facilities, 1,100 rehabilitation centers and another 5,600 facilities, from mental health to counseling centers, for a total of 26,700 facilities."
Antimicrobial resistance is the phenomenon whereby a microorganism becomes resistant to the activity of an antimicrobial drug originally effective in treating infections caused by it. The phenomenon can affect all types of antimicrobial drugs: antibacterial (also called antibiotics), antifungal, antiviral, antiparasitic. According to the WHO, AMR represents one of the greatest threats to public health today due to the epidemiological and economic impact of the phenomenon. The epidemiological impact is related to the increase in morbidity and mortality associated with infections caused by antibiotic-resistant bacteria. The most recent and comprehensive analysis carried out on behalf of the British Government has calculated that the effects of AMR cause about 50,000 deaths each year in Europe and the United States alone, in addition to hundreds of thousands of deaths in other areas of the world. In the same analysis, it was also estimated that, in the absence of effective interventions, the number of infections complicated by AMR could increase dramatically, resulting in the deaths of 10 million people per year by 2050. The epidemiologic impact of AMR has direct economic consequences related to loss of life and work days and increased use of health care resources for extended hospitalizations, increased use of diagnostic procedures, and often more expensive antibiotics when available. In the O'Neill Report, it was estimated that, by 2050, AMR could lead to a cumulative economic loss of between $20 and $35 billion in OECD countries.
The above considerations apply not only to the human context, but also to the veterinary context, where antibiotics are widely used and the impact of AMR is equally important. In the field of AMR, research has several areas of interest: development of new technologies, such as rapid diagnostic tests, new antibiotic therapies, new vaccines; understanding the epidemiology of resistance (the ways in which antibiotic-resistant microorganisms and/or AMR patterns emerge, select and spread); identification of effective strategies to promote the responsible use of antibiotics in all settings (human and veterinary health, agriculture); identification of strategies aimed at reducing the risk of transmission of infections in care settings or other collective settings. The results obtained show that the device Jonix CUBE is effective against several MultiDrug Resistant microorganisms, in particular: it is effective from 12 hours, leading to a reduction of the total bacterial load, both for the E. coli strain ATCC 10536 (R>5) and for the K. pneumoniae strain KPC (R>5); for the A. baumannii strain OXA-23 and P. aeruginosa OXA-48 the reduction of the bacterial load is not sufficient to demonstrate the effectiveness of the device after 12 hours (respectively R=3.1 and R=4.1) and 14 hours (respectively R=4.1 and R=4.8) of exposure, however after 16 hours of exposure for both microorganisms the reduction of the bacterial load is total demonstrating the effectiveness of the device, with R>5.